分析硫酸镁在治疗小儿哮喘患儿中的疗效和安全性

To analyze the efficacy and safety of magnesium sulfate in the treatment of children with asthma

目的分析硫酸镁在治疗小儿哮喘患儿中的疗效和安全性。方法随机选取本院收治的80例哮喘患儿参与本次实验,所有病例均来自2016年3月至2017年9月,依据随机数字表法将其均分为两组,将采取常规治疗的40例患儿设为对照组,将采取常规治疗^+硫酸镁治疗的40例的患儿设为实验组,就两组患儿的治疗效果、体液免疫指标水平、细胞免疫指标水平、不良反应发生率进行分析和比较。结果实验组患儿治疗总有效率(92.5%)显著高于对照组(67.5%),IL-2、IFN-γ显著高于对照组,IL-4、IL-5显著低于对照组,CD3^+、CD4^+、CD4^+/CD8^+显著高于对照组,CD8^+显著低于对照组,不良反应发生率(5.0%)显著低于对照组(22.5%),住院时间明显短于对照组,组间差异具有统计学意义(P<0.05)。结论对哮喘患儿给予硫酸镁治疗可取得较好的临床疗效,并能有效提升其免疫力,且用药安全性较高,建议将这一用药方案在临床中推广应用。

Objective To analyze the efficacy and safety of magnesium sulfate in the treatment of children with asthma. Methods 80 children with asthma admitted to the hospital were randomly selected to participate in this experiment. All cases were from March 2016 to September 2017. They were divided into two groups according to the random number table method. 40 children with asthma were divided into control group and 40 children with asthma treated with conventional therapy and magnesium sulfate were divided into experimental group. The therapeutic effect and humoral immune finger of the two groups were discussed. The standard level, the level of cellular immunity index and the incidence of adverse reactions were analyzed and compared. Results The total effective rate (92.5%) of the experimental group was significantly higher than that of the control group (67.5%), IL-2 and IFN-gamma were significantly higher than that of the control group, IL-4 and IL-5 were significantly lower than that of the control group, CD3^+, CD4^+, CD4^+/CD8^+ were significantly higher than that of the control group, CD8+ was significantly lower than that of the control group, the incidence of adverse reactions (5.0%) was significantly lower than that of the control group (22.5%), and the hospitalization time was significantly shorter than that of the control group. There was significant difference between groups, and statistical analysis showed statistical significance (P<0.05). Conclusion The treatment of magnesium sulfate in children with asthma can achieve better clinical efficacy, and can effectively improve its immunity, and the safety of medication is high. It is recommended to promote this application in clinical practice.